• There is a paucity of data examining the tolerance and outcome of hematopoietic stem cell transplantation (HSCT) for relapse after tositumomab/iodine-131 tositumomab. (cancernetwork.com)
  • There is a paucity of data examining the tolerance andoutcome of hematopoietic stem cell transplantation (HSCT) for relapse aftertositumomab/iodine-131 tositumomab. (cancernetwork.com)
  • Five patients received autologous HSCT: threemarrow and two peripheral blood stem cells. (cancernetwork.com)
  • CONCLUSION: These data demonstrate the feasibility of allogeneic orautologous HSCT in heavily pretreated lymphoma patients who also receivedtositumomab/iodine-131 tositumomab. (cancernetwork.com)
  • Graft versus host disease (GVHD), a severe immunogenic complication of allogeneic hematopoietic stem cell transplantation (HSCT), represents the most frequent cause of transplant-related mortality (TRM). (hindawi.com)
  • Allogeneic hematopoietic stem cell transplantation (HSCT) offers the only curative modality for many hematological disorders. (hindawi.com)
  • Acute Graft-versus-host disease (GvHD), one of the major complications of HSCT, is correlated to conditioning-induced gut barrier damage and may be predicted by pre-transplant serum citrulline level (Rashidi, BBMT 2018). (confex.com)
  • Serum citrulline was quantified by liquid chromatography in blood samples collected from consecutive patients who received an allogeneic HSCT in our institution between July 2014 and November 2019. (confex.com)
  • Body iron disorders have been reported after myeloablative conditioning in patients undergoing hematopoietic stem cell transplantation (HSCT). (karger.com)
  • In order to better understand the LPI kinetics and its determinants and implications, we undertook sequential LPI determinations before and after conditioning until engraftment in 25 auto-HSCT patients. (karger.com)
  • The most common adverse event following allogeneic hematopoietic stem cell transplantation (HSCT) is graft-versus-host disease (GVHD), which can increase morbidity and mortality in HSCT patients. (oncologynurseadvisor.com)
  • Given the potential importance of MAIT cells in control of microbial infections and protection of epithelial surfaces, we investigated MAIT cell reconstitution in 43 children who underwent hematopoietic stem cell transplantation (HSCT) after myeloablative conditioning for the treatment of malignant hematological disease. (cryostem.org)
  • Thus, we studied the safety, efficacy, and feasibility of transfer of gene modified donor T-cells shortly after allo-HSCT in two clinical trials between 2002 and 2007 and here we compare the results to unmodified donor leukocyte infusion (DLI). (frontiersin.org)
  • The aim of these trials was to provide patients with the protection of T-cells after T-cell-depleted allo-HSCT in the matched or mismatched donor setting with an option to delete transduced T-cells, if severe aGvHD occurred within the trial period. (frontiersin.org)
  • Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is applied successfully to the treatment of many hematopoietic malignancies, but remains limited by severe acute graft-versus-host-disease (aGvHD). (frontiersin.org)
  • 30,000 patients with blood-related malignancies receive HDC, which, if the response is satisfactory, could subsequently be followed by hematopoietic stem cell transplantation (HSCT). (bdbiosciences.com)
  • Hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) is a life-threatening syndrome that occurs in adult and pediatric patients after hematopoietic stem cell transplantation. (biomedcentral.com)
  • Hematopoietic stem cell transplantation and associated risk factors precipitate endothelial injury, leading to HSCT-TMA and other endothelial injury syndromes such as hepatic veno-occlusive disease/sinusoidal obstruction syndrome, idiopathic pneumonia syndrome, diffuse alveolar hemorrhage, capillary leak syndrome, and graft-versus-host disease. (biomedcentral.com)
  • COHORT I: Within 42 days after hematopoietic engraftment (both neutrophils and platelets) after autologous hematopoietic stem cell transplantation (HSCT), patients receive initial treatment with IHC. (bioseek.eu)
  • COHORT II: Patients with high-risk disease receive initial treatment with IHC within 70 days after hematopoietic engraftment (both neutrophils and platelets) after allogeneic HSCT. (bioseek.eu)
  • NK cell allo-reactivity could also be utilized in additional scenarios besides hematopoietic stem cell transplantation (HSCT) with studies in malignant glioma and neuroblastoma individuals demonstrating that NK cell infusions are safe and partially effective (12, 13). (mycareerpeer.com)
  • 5. G-CSF-treated donor CD4+ T cells attenuate acute GVHD through a reduction in Th17 cell differentiation. (kseh.kr)
  • Acute GVHD occurs most frequently 30-40 days after engraftment. (hindawi.com)
  • The histocompatibility differences between the donor and the recipient, the presence of donor's immunocompetent cells, and the inability of the recipient to reject these cells were defined as the basic pathogenic prerequisites for GVHD development by Billingham in 1966 [ 10 ]. (hindawi.com)
  • Cytotoxic T lymphocytes were determined as the cellular effectors of GVHD, and the key role of antigen-presenting cells (APCs) in T-lymphocyte activation was established during the following years [ 11 , 12 ]. (hindawi.com)
  • The current understanding of aGVHD pathogenesis can be summarized as (1) initial tissue damage induced by the conditioning regimen followed by the denudation of auto- and alloantigens accompanied by massive inflammatory cytokine secretion ("cytokine storm") activating APCs, (2) auto- and alloantigen presentation mediated by APCs together with the costimulatory signaling prime donor's cytotoxic T lymphocytes and their proliferation, and (3) the migration of activated cellular effectors toward GVHD target tissues. (hindawi.com)
  • An environment for GVHD is formed when antigen-presenting cells are activated by the patient's disease and the pretreatment destruction of cells caused by chemotherapy and radiotherapy. (oncologynurseadvisor.com)
  • Treatment focuses on blocking the expansion of donor T cells, as GVHD develops from the expansion of these cells. (oncologynurseadvisor.com)
  • CD20 antagonists deregulate B cells, which are believed to contribute to the pathogenesis of GVHD. (oncologynurseadvisor.com)
  • When CD20 antagonists decrease the amount of circulating B cells, the body may not produce as many cytotoxic T cells that can potentially induce GVHD. (oncologynurseadvisor.com)
  • The use of allogeneic hematopoietic cell transplantation (HCT) is the most potent immunotherapeutic treatment for hematologic diseases, but its practical use is impeded by acute and chronic graft-versus-host disease (GvHD). (cryostem.org)
  • Currently, allogeneic HSC transplantation has been widely used in a clinical setting, yet allogeneic transplantation often leads to graft versus host disease (GVHD) [ 1 ]. (biomedcentral.com)
  • Thus, prophylactic transfusion of donor T-cells has been included in many protocols, despite the increased risk for acute GvHD ( Kolb, 2008 ). (frontiersin.org)
  • [ 1 ] Acute GVHD describes a distinctive syndrome of dermatitis (see the image below), hepatitis, and enteritis developing within 100 days after allogeneic hematopoietic cell transplantation (HCT). (medscape.com)
  • In addition to allogeneic HCT, procedures associated with high risk of GVHD include transplantation of solid organs containing lymphoid tissue and transfusion of unirradiated blood products. (medscape.com)
  • Autologous graft versus host disease (GVHD) involving the skin of a patient's arm appeared shortly after signs of engraftment appeared. (medscape.com)
  • GvHD is commonly associated with bone marrow transplants and stem cell transplants . (wikipedia.org)
  • The white blood cells present within the transplanted tissue then attack the recipient's body's cells, which leads to GvHD. (wikipedia.org)
  • GvHD occurs when the donor's immune system's white blood cells reject the recipient. (wikipedia.org)
  • [11] About one-third to one-half of allogeneic transplant recipients will develop acute GvHD. (wikipedia.org)
  • The individual achieved remission, tolerating the routine without proof disease safely, engraftment failing, or GVHD. (mindunwindart.com)
  • That is part of the mechanism [of action of the agent,] and interfering with the CD6 costimulation is another way of blunting the inappropriate immune activity that we believe is part of the underlying pathology in GVHD," explained Koreth, who is the director of Translation Research and Stem Cell Transplantation and professor of medicine at Harvard Medical School. (onclive.com)
  • Reduced GvHD was hypothesized to be attributed to the lysis of the recipients antigen showing cells (APCs) reducing the incidence of GvHD while keeping GvL effect. (mycareerpeer.com)
  • Stem cell transplants have many benefits, but they also have risks. (cdc.gov)
  • Because stem cell transplants destroy and rebuild your immune system, they increase your risk for fungal infections. (cdc.gov)
  • Among seven allogeneic transplants,three received matched related peripheral blood stem cells and four receivedmatched unrelated marrow (n = 3) or peripheral blood (n = 1) stem cells.Allogeneic recipients received tacrolimus and methotrexate for graft-vs-hostdisease prophylaxis. (cancernetwork.com)
  • February 11, 2021 - Apamistamab conditioning treatment with targeted radioimmunotherapy to the bone marrow resulted in high rates of successful allogeneic hematopoietic stem cell transplants in patients with active, relapsed, or refractory acute myeloid leukemia. (onclive.com)
  • Apamistamab (Iomab-B) conditioning treatment with targeted radioimmunotherapy to the bone marrow resulted in high rates of successful allogeneic hematopoietic stem cell transplants in patients with active, relapsed, or refractory acute myeloid leukemia (AML), according to interim results from the phase 3 SIERRA trial, which were presented virtually at the 2021 Transplant and Cellular Therapies Meetings. (onclive.com)
  • Allogeneic transplants involve grafts from a genetically nonidentical donor of the same species and are the transplant type most often used in children. (oncologynurseadvisor.com)
  • The direct involvement of allo-reactive NK GSK1059865 cells in inducing anti-tumor effect in hematopoietic transplants was first shown in 2002 (8). (mycareerpeer.com)
  • Early reports indicated cell engraftment from bone marrow transplants into non- hematopoietic tissues in mouse to mouse and in human allogeneic bone marrow transplants. (ucl.ac.uk)
  • The idea to use transplants of dopa- ment of protocols that allow generation of fully functional mine-producing cells to substitute for the lost midbrain and safe midbrain dopamine neurons from stem cells. (lu.se)
  • Phase II trial of induction chemotherapy of pemetrexed plus split-dose cisplatin followed by pemetrexed maintenance for untreated non-squamous non-small-cell lung cancer. (shengsci.com)
  • abstract: PURPOSE:We conducted a phase II trial to evaluate the efficacy and safety of induction chemotherapy of pemetrexed plus split-dose cisplatin followed by pemetrexed maintenance for advanced non-squamous non-small-cell lung cancer (NSCLC). (shengsci.com)
  • Chemotherapy, radiation, or both are initiated prior to transplantation to enable engraftment of the transplanted cells, decrease tumor size, and reduce immunoreactivity of the recipient. (oncologynurseadvisor.com)
  • Misdiagnosis of acute hepatitis E virus (HEV) infection as drug-induced liver injury (DILI) may lead to discontinuation of effective chemotherapy. (journaltocs.ac.uk)
  • Mobilization human CD34+ cells for the purpose of donor (allogeneic) transplantation after high-dose chemotherapy is currently performed using a 4-5-day treatment cycle with G-CSF and a 1-2 day apheresis procedure. (biokine.com)
  • This approval should help establish continued treatment with Onureg as a standard component of AML therapy for adults who achieved first complete remission following chemotherapy and who cannot proceed to intensive curative therapy, like hematopoietic stem-cell transplant," principal investigator Andrew Wei, MD, PhD, of Monash University in Melbourne, Australia, said in a statement from trial sponsor Bristol-Myers Squibb. (medpagetoday.com)
  • Stem cell transplantation is performed after high-dose chemotherapy (HDC) to restore a cancer patient's blood and immune cell production capacity. (bdbiosciences.com)
  • For many hematopoietic malignancies, collection and infusion of CD34+ hematopoietic stem/progenitor cells following chemotherapy is critical. (bdbiosciences.com)
  • Hematopoietic stem cell transplantation is also sometimes used for solid tumors (eg, some germ cell tumors) that respond to chemotherapy. (msdmanuals.com)
  • Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy. (shengsci.com)
  • MST utilizes granulocyte colony-stimulating factor (G-CSF)Cmobilized, HLA mismatched donor peripheral-blood stem cells (GPBSCs) that are transfused into patients after receiving conventional chemotherapy [3]. (mindunwindart.com)
  • A complication of allogeneic hematopoietic stem cell transplant, aGVHD occurs in approximately 50% of patients who undergo this procedure. (onclive.com)
  • A Phase 3, randomized, double-blind, placebo-controlled, multicenter study, evaluating the safety, tolerability and efficacy of BL-8040 in combination with G-CSF, compared to placebo and G-CSF, for the mobilization of CD34 cells for autologous transplantation in multiple myeloma patients have already initiated. (biokine.com)
  • Multiple myeloma (MM) is a malignant plasma cell disorder with debilitating symptoms related to anemia, immunosuppression, bone destruction, and renal failure. (haematologica.org)
  • Inhibition of Sphingosine Kinase 2 Results in PARK2-Mediated Mitophagy and Induces Apoptosis in Multiple Myeloma. (dukecancerinstitute.org)
  • Therapeutic Candidate or Device Cryopreserved autologous TRAC locus 1XX BCMA-CAR T cells Indication Relapsed and Refractory Multiple Myeloma Therapeutic Mechanism Engineered T cells target and kill BCMA+ Myeloma cells Unmet Medical Need No durable treatments are available for RRMM and only ~30% of patients can access current BCMA CAR therapies. (ca.gov)
  • Eighty-two patients with advanced multiple myeloma (MM) were enrolled in 2 sequential clinical studies of 1 or 2 courses of myeloablative therapy with stem cell support. (shengsci.com)
  • abstract: PURPOSE:M30 and M65 ELISAs are proposed as surrogate biomarkers of tumour cell death in patients and are being applied increasingly in the pharmacodynamic (PD) evaluation of anticancer drugs during clinical trials. (shengsci.com)
  • Some types of fungal infections are more common than others in stem cell transplant patients. (cdc.gov)
  • Aspergillosis is the most common type of fungal infection in stem cell transplant patients, followed by Candida infection and mucormycosis, but other types of fungal infections are also possible. (cdc.gov)
  • Two malignancies were reported in patients with sickle cell disease (SCD), one of which was potentially busulfan-related. (bvsalud.org)
  • All patients except two who received reduced intensity had severe mucositis.Reversible veno-occlusive disease of the liver also developed in two patients.There was one death from graft-vs-host disease and no regimen-related mortality.Engraftment was prompt, with a median recovery of absolute neutrophil count to ³ 500/µL of 12 days (range: 11-18 days). (cancernetwork.com)
  • Six patients relapsed, includingall five autologous and one allogeneic recipients. (cancernetwork.com)
  • The safety profile of venetoclax following allogeneic hematopoietic stem cell transplantation in patients with chronic lymphocytic leukemia appears to be comparable with other reports in clinical trials. (cancernetwork.com)
  • In these patients with relapsed or refractory AML, we observed high rates of allogeneic stem cell transplant with curative intent [in] 88% of patients on the Iomab-B arm, 18% of patients who were randomized to the conventional care arm achieved complete remission and received standard of care allo-transplant, and an overall rate of 79% of allo-transplant in all enrolled patients," Boglarka Gyurkocza, MD, said in a virtual presentation. (onclive.com)
  • Investigators sought to prove with this study that targeted radiation to the marrow with apamistamab, a radioactive iodine ( 131 I)-labeled anti-CD45 antibody, could enable the successful engraftment of patients despite active disease in the marrow. (onclive.com)
  • In the study, patients with active, relapsed, refractory AML are randomized 1:1 to receive either apamistamab conditioning therapy and allogeneic HCT or conventional care. (onclive.com)
  • Shortly after conditioning, LPI levels were increased in 23 patients, with peak at day 0, returning to normal range upon engraftment in 21 patients. (karger.com)
  • Dr. Tisdale has an active research program in trying to characterize tolerance and create conditions in which patients will more easily tolerate donor cells and tissues without the need for destroying the immune system or perpetual use of immunosuppressant drugs. (nih.gov)
  • Dr. Tisdale and his colleagues recently completed a modified bone marrow transplant strategy for the first time in adult patients with sickle cell disease. (nih.gov)
  • After extracting and isolating precursor CD34+ cells from patients, they use viral transduction to insert a correct copy of the β-globin gene before returning the cells to the patient's bone marrow. (nih.gov)
  • Eight patients received conditioning with fludarabine and low-dose total body irradiation followed by hematopoietic cell transplantation from an HLA-matched sibling donor. (aacrjournals.org)
  • Patients were monitored for donor engraftment of myeloid and lymphoid cells, for clinical response by serial imaging, and for immunologic response by in vitro isolation of donor-derived CD8 + CTLs recognizing recipient minor histocompatibility (H) antigens. (aacrjournals.org)
  • Clones from three patients with a partial response or stable disease recognized antigens expressed on renal cell carcinoma tumor cells. (aacrjournals.org)
  • Treatment of metastatic renal cell carcinoma with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning with fludarabine/total body irradiation is feasible and may induce tumor regression or stabilization in some patients. (aacrjournals.org)
  • Under normal conditions the CXCR4 pathway regulates the hematopoietic stem cell niche in the bone marrow (BM)-a property that has led to the approval of the CXCR4 antagonist plerixafor together with G-CSF (AMD3100, Mozobil) for mobilization from the BM and collection of hematopoietic precursors from the blood for transplantation of myeloma and lymphoma patients. (biokine.com)
  • On the other hand, bulk RNA-sequence analyses reveal that gene expression profiles among patients are different according to the cytomegalovirus reactivation pattern, and are associated with cytokine production or cell division. (nature.com)
  • It should be administered under the supervision of a qualified physician who is experienced in allogeneic hematopoietic stem cell transplantation, the use of cancer chemotherapeutic drugs and the management of patients with severe pancytopenia. (nih.gov)
  • The pharmacokinetics of BUSULFEX were studied in 59 patients participating in a prospective trial of a BUSULFEX-cyclophosphamide preparatory regimen prior to allogeneic hematopoietic progenitor stem cell transplantation. (nih.gov)
  • Donor chimerism was stabilized after transfusion of the transduced cells in all patients treated. (frontiersin.org)
  • To date, six patients have relapsed and died, two after a second hematopoietic stem cell transplantation without T-cell depletion or administration of unmodified T-cells. (frontiersin.org)
  • NEW ORLEANS - Retinal pigment epithelial (RPE) cells derived from human embryonic stem cells can be safely transplanted into the eyes of patients with retinal degeneration, with early signs of vision gain, according to pioneers in the field. (medscape.com)
  • Patients had the dry form of age-related macular degeneration (AMD) or Stargardt disease and received injections of human embryonic stem-cell (hESC)-derived RPE cells. (medscape.com)
  • While some patients in her study have gained vision, Ninel Z. Gregori, MD, from Bascom Palmer Eye Institute, Miami, Florida, said, "These trials show long term safety and possible biologic activity of pluripotent stem-cell derived progeny, but they were not powered to show efficacy. (medscape.com)
  • In both studies presented here, human embryonic stem cells were turned into RPE cells and injected into the subretinal space of patients with retinal degeneration at a dose of 50,000 to 200,000 cells. (medscape.com)
  • Dr Gregori and her multi-institutional team conducted two phase 1/2 trials using hESC-derived RPE cells, one in dry AMD patients (n = 13) and the other in Stargardt disease (n = 13). (medscape.com)
  • The 20 patients with poor visual acuity (≤ 20/400) received 50,000 to 200,000 RPE cells, and the six patients with better vision (≤ 20/100) received 100,000 cells. (medscape.com)
  • Of the 26 patients, 24 (92%) developed areas of subretinal pigmentation that did not correlate with cell dose or visual acuity outcomes. (medscape.com)
  • Six patients demonstrated preretinal pigmented cells near the site of injection. (medscape.com)
  • Median OS improved by almost 8 months among patients with AML and myelodysplasia-related changes (AML-MRC) treated with liposomal cytarabine-daunorubicin (CPX-351, Vyxeos) versus conventional 7 + 3 induction therapy, as reported at the Transplantation and Cellular Therapy Meetings . (medpagetoday.com)
  • Results Natural killer cells from healthy donors and myeloma patients expanded a median of 804- and 351-fold, respectively, without significant T-cell expansion. (haematologica.org)
  • 1 Significant advances have been made by combining novel agents with autologous peripheral blood stem cell transplantation which allows for long-term disease-free survival in the majority of transplant-eligible patients. (haematologica.org)
  • Indication The target indication is for the transplantation of patients with severe X-linked Chronic Granulomatous Disease (XCGD) lacking matched donors. (ca.gov)
  • Therapeutic Candidate or Device Allogeneic iPSC derived dopamine progenitors delivered to the brain of Parkinson's disease patients Indication Idiopathic Parkinson's disease Therapeutic Mechanism The cellular product reconstitutes dopaminergic neuron circuits lost owing to the disease Unmet Medical Need There are currently disease modifying therapies. (ca.gov)
  • Prior attempts to transplant β cells to restore glycemic control to T1D patients have used cadaveric- and porcine-derived cells. (jax.org)
  • This pilot clinical trial studies the side effects of irradiated donor cells following stem cell transplant in controlling cancer in patients with hematologic malignancies. (bioseek.eu)
  • Transfusion of irradiated donor cells (immune cells) from relatives may cause the patient's cancer to decrease in size and may help control cancer in patients receiving a stem cell transplant. (bioseek.eu)
  • I. To determine the toxicity associated with the administration of irradiated haploidentical cells (IHC) to patients with high-risk hematologic malignancies. (bioseek.eu)
  • Between February 1986 and March 1990, 56 patients with relapsed Hodgkin's disease treated with high-dose cyclophosphamide, carmustine, and etoposide (CBV) received an autologous peripheral stem cell transplantation (PSCT) rather than an autologous bone marrow transplantation (ABMT) because each patient had a marrow abnormality, either hypocellularity or tumor involvement. (shengsci.com)
  • Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation. (shengsci.com)
  • One great advantage of MSC is that these cells may be directly obtained from individual patients, thereby eliminating the complications associated with immune rejection of allogenic tissue and infectious diseases. (biomedcentral.com)
  • Itolizumab, a first-in-class anti-CD6 monoclonal antibody targets the CD6-activated leukocyte cell adhesion molecule (ALCAM) pathway, which modulates the activity of T cells that drive immunoinflammatory diseases, and has demonstrated early activity as a first-line therapy for patients with high-risk aGVHD in the phase 1/2 EQUATE trial (NCT03763318). (onclive.com)
  • The clinical presentation of patients with aplastic anemia includes signs and symptoms related to the decrease in bone marrow production of hematopoietic cells. (medscape.com)
  • In early 2009, the FDA approved the first human clinical trials using embryonic stem cells. (wikipedia.org)
  • Her clinical and translational research explores whether certain immune cells called natural killer (also known as NK cells) can prevent relapse and treat high-risk cancers. (seattlechildrens.org)
  • These methods and results can help us to better understand immune reconstitution following hematopoietic cell transplantation, leading to future studies on the clinical application of adoptive T-cell therapies. (nature.com)
  • A better and deeper understanding of immune reconstitution following allo-HCT is required for further clinical application of these adoptive T-cell therapies. (nature.com)
  • Altogether, our findings lay a foundation for improving the efficiency of hematopoietic differentiation and generating in vivo functional HSC-like cells from mouse PSCs for clinical application. (biomedcentral.com)
  • Tumor stem cell-targeted immunotherapy for metastatic melanoma -a randomized phase 3 clinical trial. (ca.gov)
  • Blood and Marrow Transplant Research [CIBMTR] in 2004), the European Research Project on Cord Blood Transplantation (Eurocord) in 1993, and the Japanese Cord Blood Banking Network in 1996-expedited the clinical evaluation of the efficacy and safety of transplantation of cord blood from unrelated donors. (nationalacademies.org)
  • RQR8 is a 136-amino-acid epitope-based marker/suicide gene that enables clinical selection, cell tracking, and deletion in case of toxicity. (ashpublications.org)
  • A compact marker/suicide gene that utilizes established clinical-grade reagents and pharmaceuticals would be of considerable practical utility to T-cell cancer gene therapy. (ashpublications.org)
  • Pharmacogenomics of drug-induced liver injury (DILI): Molecular biology to clinical applications. (cdc.gov)
  • Clinical Utility of Quantitative PCR for Chimerism and Engraftment Monitoring after Allogeneic Stem Cell Transplantation for Hematologic Malignancies. (cdc.gov)
  • In recent years, clinical trials with stem cells have taken the emerging field in many new directions. (biomedcentral.com)
  • The rapid advance of stem cell clinical trials for a broad spectrum of conditions warrants an update of the review by Trounson (2009) [ 1 ]. (biomedcentral.com)
  • There has been a rapid surge in clinical trials involving stem cell therapies over the last two to three years and those trials are establishing the clinical pathways for an emergent new medicine. (biomedcentral.com)
  • Placenta-derived stem cells are being considered for similar uses and are in Phase III clinical trial for critical limb ischemia by Israel's Pluristem Therapeutics. (biomedcentral.com)
  • A significant proportion of clinical studies that are underway involve bone marrow and cord blood stem cells for blood and immune disorders [ 3 ] and cancers. (biomedcentral.com)
  • We have chosen to concentrate on the emerging therapeutics that broadly involves a wide range of cell types in clinical trials registered on the National Institutes of Health's clinical trials web site. (biomedcentral.com)
  • Adipose tissue (AT) represents a commonly used source of mesenchymal stem/stromal cells (MSCs) whose proregenerative potential has been widely investigated in multiple clinical trials worldwide. (mdpi.com)
  • Despite almost 50 years of research and over 20 years of preclinical and clinical studies, the question of curative potential of mesenchymal stem/stromal cells (MSCs) is still widely discussed in the scientific community. (frontiersin.org)
  • Only a careful consideration and standardization of all pretreatment processes/methods for the different applications of MSCs will ensure robust and reproducible performance of these cell populations in the different experimental and clinical settings. (frontiersin.org)
  • We have recently demonstrated in a Phase I study in healthy volunteers that single dose of the CXCR4 antagonist BL-8040 induces a rapid and robust mobilization and mega dose collection of human CD34+ stem and progenitor cells. (biokine.com)
  • Although hematopoietic stem and progenitor cells (HSPCs) enable autologous treatment of blood disorders, de novo generation of hematopoietic cells from pluripotent stem cells still compromises the unlimited high yield and rich hematopoiesis engraftment potential [ 2 ]. (biomedcentral.com)
  • CD34, a transmembrane phosphoglycoprotein, is present on immature hematopoietic precursor cells and all hematopoietic colony-forming cells in bone marrow and blood, including unipotent and pluripotent progenitor cells. (bdbiosciences.com)
  • Flow cytometric enumeration of CD34+ HSCs and progenitor cells is an established method for the evaluation of bone marrow and stem cell grafts. (bdbiosciences.com)
  • Therapeutic Candidate or Device The therapeutic product candidate is autologous CD34+ hematopoietic stem/progenitor cells (HSPC) transduced with the G1XCGD lentiviral vector. (ca.gov)
  • B lood cell differentiation begins with multipotent hematopoietic progenitor cells (HPCs), which are located in the marrow spaces of the bone. (nationalacademies.org)
  • As the cells reproduce, they commit to a particular task or cell line and become known as committed progenitor cells . (nationalacademies.org)
  • These committed progenitor cells are difficult to discern from the original multipotent cells but can be cultured to form colonies of specific types of blood cells (Guyton and Hall, 2000). (nationalacademies.org)
  • Umbilical cord blood is a rich source of these committed progenitor cells and, presumably, multipotent HPCs (Knudtzon, 1974). (nationalacademies.org)
  • If healthy muscle progenitor cells were introduced and could fuse to existing deficient fibers, as well as form new muscle fibers, regeneration of muscle might occur 11 , 12 . (plos.org)
  • Many less controversial sources of acquiring stem cells include using cells from the umbilical cord, breast milk, and bone marrow, which are not pluripotent. (wikipedia.org)
  • Para la recolección de datos, se utilizaron los cuestionarios Functional Assessment Cancer Therapy Bone Marrow Transplantation y el COmprehensive Score for financial Toxicity. (bvsalud.org)
  • The three sources of stem cells include bone marrow, umbilical cord blood, and peripheral blood. (oncologynurseadvisor.com)
  • The Cellular and Molecular Therapeutics Laboratory, led by Dr. John F. Tisdale, is working on multiple strategies both in the laboratory and in the clinic to cure sickle cell disease by repairing or replacing the precursor bone marrow cells that give rise to sickled red blood cells. (nih.gov)
  • In a recent study, they demonstrated that they could transplant bone marrow cells from HLA-matched sibling donors without needing to completely destroy the patient's immune system. (nih.gov)
  • Peripheral blood has largely replaced bone marrow as a source of stem cells, especially in autologous hematopoietic stem cell transplantation, because stem cell harvest is easier and neutrophil and platelet counts recover faster. (msdmanuals.com)
  • Bone marrow transplantation. (umn.edu)
  • While numerous teams continue to refine and expand the role of bone marrow and cord blood stem cells for their vanguard uses in blood and immune disorders, many others are looking to expand the uses of the various types of stem cells found in bone marrow and cord blood, in particular mesenchymal stem cells, to uses beyond those that could be corrected by replacing cells in their own lineage. (biomedcentral.com)
  • There are many studies involving autologous therapies and some allogenic therapies, based on the recovery of mobilized bone marrow cells, including mesenchymal stem cells (MSCs) and adipose derived stem cells that also include the stromal or adherent cell type that has an MSC phenotype. (biomedcentral.com)
  • The use of patient's own bone marrow aspirates, hematopoietic stem cells and MSCs, for heart muscle tissue repair can be puzzling because these cells do not normally contribute to the cardiac lineage types that are desired. (biomedcentral.com)
  • Human stem cells introduced into the NOD/Scid mouse after partial myeloablation repopulate the bone marrow and contribute to the hematopoietic system of the mouse. (ucl.ac.uk)
  • Engraftment into the bone marrow was measured by FACS and human genetic material was found in the spleen, skin, lung and liver. (ucl.ac.uk)
  • Liver damage has been suggested as one of the factors influencing homing of stem cells to the liver and transdifferentiation of bone marrow cells into hepatocytes. (ucl.ac.uk)
  • However, transdifferentiation defined as the emergence of mature human hepatocytes after bone marrow transplantation could not be found. (ucl.ac.uk)
  • I conclude that transdifferentiation of human stem cells to a mature hepatocyte phenotype does not occur in the NOD/Scid model of bone marrow transplantation even after severe CCU induced liver damage. (ucl.ac.uk)
  • Low-power view of hematoxylin-eosin-stained bone marrow showing hypocellularity, with increased adipose tissue and decreased hematopoietic cells in the marrow space. (medscape.com)
  • The theoretical basis for marrow failure includes primary defects in or damage to the stem cell or the marrow microenvironment. (medscape.com)
  • External insults (eg, infections, radiation, drugs) may disrupt stem cell homeostasis in marrow environment, leading to altered growth. (medscape.com)
  • Low power, H and E showing a hypocellular bone marrow with increased adipose tissue and decreased hematopoietic cells in the marrow space. (medscape.com)
  • The expectation is that, once in place, the new RPE cells will support or replace the patient's own failing RPE cells and boost the survival of photoreceptors. (medscape.com)
  • Hematopoietic stem cell transplantation may be autologous (using the patient's own cells) or allogeneic (using cells from a donor). (msdmanuals.com)
  • In autoimmune type 1 diabetes (T1D), a patient's own T cells destroy the insulin-producing β cells in the pancreas, leading to progressively worse hyperglycemia. (jax.org)
  • Stem cells had been produced from the patient's godson, who been 29-year-old, unrelated donor with full HLA mismatch. (mindunwindart.com)
  • 10. Granulocyte colony-stimulating factor-induced immature myeloid cells inhibit acute graft-versus-host disease lethality through an indoleamine dioxygenase-independent mechanism. (kseh.kr)
  • RESULTS: We identified eight pediatric and 13 adult publications describing long-term follow-up in 570 pediatric and 2076 adult hematopoietic cell transplant (HCT) recipients. (bvsalud.org)
  • The other three allogeneic recipients died from either graft-vs-hostdisease, relapse, or acetaminophen-induced hepatic necrosis. (cancernetwork.com)
  • The conditioning-induced damage of recipients' tissues leads to danger signal secretion [ 13 ]. (hindawi.com)
  • In a Phase II study single-agent treatment with BL-8040 showed similar efficacy and non-inferiority in recipient engraftment, with all transplanted recipients successfully engrafting with BL-8040-mobilized grafts. (biokine.com)
  • Here we show the features of repertoire diversity and the gene expression profile of HLA-A24 cytomegalovirus-specific cytotoxic T-cells in actual recipients according to the cytomegalovirus reactivation pattern. (nature.com)
  • 2019 sickle cell disease guidelines by the American Society of Hematology: methodology, challenges, and innovations. (nih.gov)
  • CD34-selection of stem cells reduces the risk of aGvHD, but also leads to increased infectious complications and relapse. (frontiersin.org)
  • Previous studies have shown that children with acute myeloid leukemia (AML) who developed mixed chimerism (MC) were at high risk for relapse after allogeneic stem-cell transplantation (allo-SCT). (shengsci.com)
  • 7. Protective role of V-set and immunoglobulin domain-containing 4 expressed on kupffer cells during immune-mediated liver injury by inducing tolerance of liver T- and natural killer T-cells. (kseh.kr)
  • Long-term engraftment of allogeneic cells necessitates eluding immune-mediated rejection, which is currently achieved by matching for human leukocyte antigen (HLA) expression, immunosuppression, and/or delivery of donor-derived cells to sanctuary sites. (ashpublications.org)
  • The issue of immune tolerance is, of course, central to transplantation research. (nih.gov)
  • Cytomegalovirus reactivation is still a critical concern following allogeneic hematopoietic cell transplantation, and cellular immune reconstitution of cytomegalovirus-specific cytotoxic T-cells is necessary for the long-term control of cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation. (nature.com)
  • However, cellular immune reconstitution of CMV-specific cytotoxic T-cells (CMV-CTL) is generally considered to be necessary for the long-term control of CMV reactivation after allo-HCT. (nature.com)
  • White blood cells of the donor's immune system which remain within the donated tissue (the graft) recognize the recipient (the host) as foreign (non-self). (wikipedia.org)
  • One concern about the procedure is that immune cells in cord blood do not have experience with the viruses responsible for latent infections, leading to a higher percentage of naive T cells and thus increased vulnerability to reactivation of cytomegalovirus or Epstein-Barr virus infection. (msdmanuals.com)
  • Researchers and clinicians have long sought a method to replace the β cells, but these efforts have been hindered by the difficulty in developing a reliable and sustainable donor b cell source and a way to engraft them that avoids both immune-mediated allogeneic rejection and continuing autoimmune b cell destruction. (jax.org)
  • Following engraftment, the encapsulated human cells escaped xenogeneic immune destruction and maintained stable long-term glycemic control for up to six months. (jax.org)
  • These cells typically do not maintain long-term glycemic control because they stimulate strong host-mediated immune reactions leading to cell necrosis and fibrosis. (jax.org)
  • Researchers have attempted encapsulating donor β cells in a variety of materials to prevent allo- and xenogeneic rejection, but these materials themselves can stimulate innate immune responses. (jax.org)
  • In a separate experiment, SC-β cell-loaded unmodified and TMTD-modified alginate microspheres were isolated from engrafted mice 14 days post-engraftment, and the presence of host immune cells adhering to the microspheres was examined by flow cytometry. (jax.org)
  • The smallest (0.5 mm) unmodified spheres showed the greatest number of associated immune cells. (jax.org)
  • Together, these data demonstrate that the TMTD-modified, larger microspheres induced significantly less innate immune cell stimulation and reduced fibrosis. (jax.org)
  • I. To determine if treatment with the irradiated cells induces an immune response targeting tumor associated epitopes. (bioseek.eu)
  • Transduction of CLL cells by CD40 ligand enhances an antigen-specific immune recognition by autologous T cells. (shengsci.com)
  • By doing so, it appears to switch them from a proinflammatory immune effector cell to a less inflammatory, regulatory T-cell phenotype. (onclive.com)
  • This includes bone and cartilage repair, cell types into which MSCs readily differentiate, and immune conditions such as graft versus host disease and autoimmune conditions that utilize the MSC's immune suppressive properties. (biomedcentral.com)
  • To facilitate gene and cell therapy experiments, we created severely immune-deficient mouse models of Duchenne muscular dystrophy (DMD), limb girdle muscular dystrophy 2B (LGMD2B), and limb girdle muscular dystrophy 2D (LGMD2D) by crossing mdx 4Cv , Bl/AJ, and Sgca-null mice with NRG immune-deficient mice. (plos.org)
  • These novel immune-deficient mouse models of DMD, LGMD2B, and LGMD2D will be useful for long-term gene and cell therapy studies involving transfer of foreign genes and cells. (plos.org)
  • Therapeutic Candidate or Device The therapeutic candidate is a patient specific (autologous) induced pluripotent stem cell derived retinal pigment epithelium (AiPSC-RPE) product. (ca.gov)
  • CD8 + CTL-recognizing minor H antigens on tumor cells can be isolated posttransplant and could contribute to the graft- versus -tumor effect. (aacrjournals.org)
  • VM), showed that the recovery of motor functions induced implanted either (1) as a solid piece in the lateral ven- by the grafted fetal dopamine neurons was well cor- tricle6 or a cortical cavity8 adjacent to the denervated related with the extent of graft-derived reinnervation caudate-putamen, or (2) as a crude cell suspension of the host caudate-putamen. (lu.se)
  • Evidence suggests that the CXC-chemokine receptor-4 (CXCR4) pathway plays a major role in cancer cell homing and metastasis and in shaping the tumor microenvironment (TME), and thus represents a potential target for cancer therapy. (biokine.com)
  • Thioredoxin-1 regulates self-renewal and differentiation of murine hematopoietic stem cells through p53 tumor suppressor. (dukecancerinstitute.org)
  • Therapeutic Candidate or Device Tumor stem cell-targeted immunotherapy. (ca.gov)
  • Therapeutic Mechanism Destruction of host tumor stem cells by adaptive humoral cellular immunity will eradicate the origin of melanoma which will extend patient survival. (ca.gov)
  • Tumor clearance was accomplished implicating NK cells in conserving the GvL effect (9). (mycareerpeer.com)
  • HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation. (cdc.gov)
  • This shown that NK cell infusions were feasible and safe and led to total remission in 5/19 individuals with poor prognosis AML (10). (mycareerpeer.com)
  • To assess the role of tissue damage a model of severe liver injury induced by CCU was utilised. (ucl.ac.uk)
  • HLA-A disruption from donor cells is a step toward generating allogeneic cells as an off-the-shelf therapeutic. (ashpublications.org)
  • Therapeutic Candidate or Device Tissue implant engineered using expanded, allogeneic chondroprogenitor cells Indication Defects of the temporomandibular joint disc complex Therapeutic Mechanism Though the mechanism has not been established, Hyaleon®️ may initially act as a load bearing structure that fills defects of the temporomandibular joint (TMJ) disc complex. (ca.gov)
  • Therapeutic Candidate or Device Rebecsinib is a novel small molecule inhibitor of ADAR1 splicing that selectively eradicates therapy-resistant cancer stem cells in blood cancers. (ca.gov)
  • With a variety of assays we could show that MSC represent a cell population which can be expanded for therapeutic applications. (biomedcentral.com)
  • In recent years mesenchymal stem cells (MSC) have generated a great deal of interest as a potential source for cell-based therapeutic strategies. (biomedcentral.com)
  • Human amniotic membrane and amniotic membrane-derived mesenchymal stromal cells (hAMSCs) have produced promising results in regenerative medicine, especially for the treatment of inflammatory-based diseases and for different injuries including those in the orthopedic field such as tendon disorders. (mdpi.com)
  • Human mesenchymal stem cells (MSC) with the capacity to differentiate into osteoblasts provide potential for the development of novel treatment strategies, such as improved healing of large bone defects. (biomedcentral.com)
  • Mesenchymal stem/stromal cells (MSCs) have the capacity to differentiate into cells and tissues of one germ layer, here the mesodermal lineage, and are consequently multipotent. (frontiersin.org)
  • 14. Murine keratocytes function as antigen-presenting cells. (kseh.kr)
  • 1 After transplantation, donor T cells are activated by antigen-presenting cells. (oncologynurseadvisor.com)
  • Extracorporeal photopheresis inactivates antigen-presenting cells and T cells, whereas TNF antagonists decrease cellular activation and local tissue damage. (oncologynurseadvisor.com)
  • 4 One of the primary pathways in which T cells are activated is through antigen-presenting cells such as B cells. (oncologynurseadvisor.com)
  • We also know that the ligand called ALCAM, is expressed on antigen-presenting cells, as well as the inflamed tissues in the skin and GI tract. (onclive.com)
  • In certain circumstances, MAIT cells are also able to produce IL-22, a cytokine involved in gut epithelial protection during inflammatory intestinal damage. (cryostem.org)
  • This phenomenon is TLR9 often experienced in haploidentical stem AR-C69931 cost cell transplantation where the mismatch of HLA-antigens induces cytokine launch and fever [6]. (mindunwindart.com)
  • Stem cells from your own body (also called an autologous transplant). (cdc.gov)
  • Yet further treatments using stem cells could potentially be developed due to their ability to repair extensive tissue damage. (wikipedia.org)
  • Adult stem cells are generally limited to differentiating into different cell types of their tissue of origin. (wikipedia.org)
  • These early trials are showing roles for stem cells both in replacing damaged tissue as well as in providing extracellular factors that can promote endogenous cellular salvage and replenishment. (biomedcentral.com)
  • To achieve true transdifferentiation a different, more chronic type of tissue damage, or a better defined stem cell population might be required. (ucl.ac.uk)
  • Non-reproducible treatment outcomes or even absence of treatment effects in comparison to control groups challenges the potential of these cells for routine application both in tissue engineering and in regenerative medicine. (frontiersin.org)
  • This phase I trial assessed the safety, efficacy, and immunologic responses to minor histocompatibility antigens following nonmyeloablative allogeneic hematopoietic cell transplantation as treatment for metastatic renal cell carcinoma. (aacrjournals.org)
  • Several types of malignancy could therefore benefit from NK cell immunotherapy and current medical trials include pancreas, lungs, head/neck, breast, and renal cell carcinomas. (mycareerpeer.com)
  • Chronic myelogenous leukemia (CML), also known as chronic myeloid leukemia, is a myeloproliferative disorder characterized by increased proliferation of the granulocytic cell line without the loss of their capacity to differentiate. (medscape.com)
  • This was later successfully translated into an model using acute myeloid leukemia (AML)-engrafted NOD/SCID mice infused with allo-reactive Rabbit Polyclonal to RPS6KB2 NK cells. (mycareerpeer.com)
  • In this study, we established an in vitro differentiation system yielding in vivo hematopoietic reconstitution hematopoietic cells from mouse PSCs through a 3D induction system followed by coculture with OP9 stromal cells. (biomedcentral.com)
  • Chronic Granulomatous Disease-Associated IBD Resolves and Does Not Adversely Impact Survival Following Allogeneic HCT. (seattlechildrens.org)
  • The Hematopoietic Cell Transplant Comorbidity Index predicts survival after allogeneic transplant for nonmalignant diseases. (seattlechildrens.org)
  • Gastrointestinal toxicity occurs during the neutropenic (pre-engraftment) period. (hindawi.com)
  • Marker genes enable detection and selection of T cells, whereas suicide genes enable selective destruction of T cells in case of toxicity. (ashpublications.org)
  • Marker genes enable measurement of transduction and allow selection of transduced cells, whereas suicide genes allow selective deletion of administered T cells in the face of toxicity. (ashpublications.org)
  • But this is just a first step in the long road towards making regenerative cell therapy a reality in macular and retinal degeneration. (medscape.com)
  • We predict that RQR8 will make T-cell gene therapy both safer and cheaper. (ashpublications.org)
  • Genetic engineering of T cells greatly increases the scope and potency of T-cell therapy: T-cell receptor (TCR) transfer allows targeting of intracellular cancer antigens, whereas chimeric antigen receptors (CARs) allow targeting of surface cancer or lineage-specific antigens. (ashpublications.org)
  • One promising alternative to alloSCT AR-C69931 cost is a form of HLA-mismatched allogeneic cellular therapy known as microtransplantation (MST) [2]. (mindunwindart.com)
  • Medical tests using autologous NK cells have shown the therapy to be nontoxic, however, they fail to show efficacy (7), which could become the result of inhibition by self-MHC-I. Allogeneic treatment therefore offers potential to offer an alternative therapy with improved effect. (mycareerpeer.com)
  • Miller and colleagues later on translated NK cell therapy only into the medical center where allogeneic NK cells were infused into individuals with advanced malignancy alongside IL-2 administration. (mycareerpeer.com)
  • Additionally, the effectiveness of haploidentical NK cell therapy in the refractory disease was further improved by depleting sponsor regulatory T cells with IL-2 diphtheria toxin avoiding their immunosuppressive effect (11). (mycareerpeer.com)
  • However, the standardization of the manufacturing process of MSC-based cell therapy medicinal products in compliance with the requirements of the local authorities is obligatory and will allow us to obtain the necessary permits for product administration according to its intended use. (mdpi.com)
  • Moreover, gene therapy strategies typically do not correct muscle stem cells 10 . (plos.org)
  • In these settings, cell therapy strategies designed to restore healthy muscle cells may have value. (plos.org)
  • The specific medications administered depend on the choice of therapy and whether it is supportive care only, immunosuppressive therapy, or hematopoietic cell transplantation. (medscape.com)
  • Cell Therapy for Parkinsons Disease: What Next? (lu.se)
  • I demonstrate that stem cell homing to the liver is significantly increased upon liver injury. (ucl.ac.uk)
  • Cytotoxic T cells mount a response on the body and target recipient cells are lysed. (oncologynurseadvisor.com)
  • Single-cell RNA-sequence analyses demonstrate the homogenous distribution of the gene expression profile in individual cytomegalovirus-specific cytotoxic T-cells within each recipient. (nature.com)
  • Consistently fewer macrophages, neutrophils, β cells, and cytotoxic T cells were associated with TMTD alginate spheres compared to unmodified alginate spheres. (jax.org)